The Annual General Meeting of BioGaia AB (publ) on 7 May 2025 voted, among other things, to approve the following resolutions:

- adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet

- discharge from liability for the Board members and the CEO

- a dividend of SEK 1.95 per share plus an extra dividend of SEK 4.95 per share resulting in a total dividend of SEK 6.90 per share and a grant of SEK 5.0 million to "The Foundation to Prevent Antibiotic Resistance" that was founded by BioGaia in 2017. The purpose of the foundation is to reduce antibiotic resistance through support to research, education and information activities that promote of the use of products and methods that prevent and therefore reduce the use of antibiotics and the risk of antibiotic resistance

- the number of Board members shall be seven without deputies and re-election of Anthon Jahreskog, Bénédicte Flambard, David Dangoor, Peter Rothschild, Vanessa Rothschild, Barbro Fridén and Outi Armstrong as Board members

- re-election of Peter Rothschild as Board chairman and David Dangoor as deputy Board chairman

- the auditor shall be a registered accounting firm and re-election of the registered accounting firm Deloitte AB

- board member remuneration in an amount of SEK 950,000 to the Board chairman, SEK 530,000 to the deputy Board chairman, SEK 302,000 to each of the other Board members elected by the general meeting, SEK 142,000 to the chairman of the audit committee and SEK 71,000 each to the other members of the audit committee and SEK 52,000 to the chairman of the remuneration committee and SEK 26,000 to each to the other members of the remuneration committee

- auditors' fee shall be paid according to approved account

- on a nominating committee in accordance with the nominating committee's proposal,

- approval of the Board of Director's remuneration report

- to implement performance share program 2025/2028, regarding a directed issue of warrants to the company to ensure delivery of shares and to cover any cash flow effects resulting from social security contributions in connection with the program, and regarding approval of the transfer of warrants or shares to participants in the program. The detailed terms and conditions of the program are set out in the notice to the general meeting and in the minutes that will be published on the company's website

- to adopt new articles of association, in which a conversion clause relating to the company's Class B shares has been added.
 

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Alexander Kotsinas, CFO
Email: alexander.kotsinas@biogaia.com
Phone: +46(0)735 00 11 11

Theresa Agnew, President and CEO
Email: tpa@biogaia.se
Phone: +46(0)8 555 293 00

About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com